Study Examines New Flu Vaccine for Older Adults

MAIDENHEAD, United Kingdom – A new influenza vaccine for older adults has undergone review in a Phase 3 study, with findings published in The Lancet. CSL Seqirus, a CSL business, announced the publication on September 10, 2026.

The vaccine combines three methods designed to improve protection for individuals aged 65 and older. These approaches include a higher antigen dose, the use of an adjuvant, and a recombinant hemagglutinin (HA) protein.

Researchers conducted the study to assess the vaccine's ability to prevent influenza. They focused on adults in the 65 and over age group, a population segment known for experiencing more severe outcomes from influenza infections.

CSL Seqirus developed the vaccine. The company stated that the study provided data regarding its performance. This development represents an ongoing effort within the medical community to enhance influenza prevention strategies for vulnerable populations.